Insulin improves experimental stem-cell and vesicle effects in diabetic mice
Published in Biology, Drugs development & discovery, Immunology, Journals.
Published November 2, 2026.
A Cell Death & Disease study published today explores why insulin can improve the durability of experimental mesenchymal stem-cell treatment in mouse models of type 2 diabetes.
Hu and colleagues tested umbilical cord-derived mesenchymal stem cells in db/db mice and diet-induced obese mice. Cells alone produced short-term metabolic improvements, whereas combining them with insulin produced more sustained glycemic benefits and reduced several metabolic complications under the tested conditions.
The proposed mechanism involves early programmed death of the administered cells. Under high glucose, insulin increased production of apoptotic vesicles, changed their molecular cargo and strengthened their effects on macrophages toward an anti-inflammatory state. Administering cell-derived vesicles also produced sustained benefits in the mouse experiments.
The work suggests that a therapeutic cell’s controlled death and released material can matter as much as its survival. These are preclinical results: they do not establish efficacy or safety of stem cells or vesicles for people with diabetes, or support changing prescribed insulin treatment.
The authors report no competing interests. This peer-reviewed accepted article remains subject to editorial changes.
Source: Hu et al., Cell Death & Disease, November 2, 2026.